A Prospective, Randomized, Open-Label, Comparative Clinical Trial in Post-Surgical Melanoma Patients With Either DNP-Modified Autologous Tumor Vaccine or Interferon Alpha-2b

NCT00003715 Phase 2 TERMINATED

RATIONALE: Vaccines made from a person's melanoma cells may make the body build an immune response to kill tumor cells. Interferon alfa may interfere with the growth of the cancer cells. PURPOSE: Randomized phase III trial to compare the effectiveness of melanoma vaccine with that of interferon alfa-2b in treating patients who have stage III melanoma that has spread to regional lymph nodes following surgery.

Details

Lead sponsor	AVAX Technologies
Phase	Phase 2
Status	TERMINATED
Enrolment	425
Start date	1998-12

Conditions

• Melanoma (Skin)

Interventions

• BCG vaccine
• autologous tumor cell vaccine
• recombinant interferon alfa
• chemotherapy
• cyclophosphamide

Countries

United States